Another cohort study revealed that the median overall survival (mOS) of patients with NSCLC who received ICI therapy, such as epidermal growth factor receptor (EGFR)-TKI therapy, following tyrosine kinase inhibitor (TKI) treatment was significantly shorter than that of patients who did not receive TKIs (7.6 months vs. 18.5 months). This evidence concerns the gene EGFR and non-small cell lung carcinoma.